Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Purpose
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Early Stage Triple-Negative Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Participants must have histologically confirmed estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and HER2-negative breast cancer (TNBC) defined
as ER < 5%, PR < 5%, and HER2 negative (per 2020 American Society of Clinical
Oncology [ASCO] College of American Pathologists [CAP] guidelines)
- NOTE: Participants with weakly ER or PR positive disease, defined as ER and/or
PR between 1-4% by immunohistochemistry, are eligible if adjuvant endocrine
therapy is not recommended/planned by the treating physician
- Participants must have American Joint Committee on Cancer (AJCC) 8 anatomic tumor
clinical stage either
- T2-T4, N0, M0 or
- T1-T3, N1-2, M0
- Note: All participants with clinically suspicious nodes must undergo core
needle biopsy or fine needle biopsy per standard clinical practice to
pathologically confirm nodal status
- Participants must have breast and axillary imaging with mammogram and/or ultrasound
and/or magnetic resonance imaging (MRI) within 49 days prior to randomization
- Note: Participants with bilateral invasive breast cancer are eligible if both
breast cancers are ER-negative, PR-negative, and HER2-negative provided they
meet the other eligibility criteria
- Participants must not have T4/N+, any N3, or inflammatory breast cancer
- Participants must not have metastatic disease (M1)
- Participants must not have received prior systemic therapy or radiation therapy with
curative intent for the current breast cancer
- Participants must not have had previous definitive ipsilateral breast surgery for
the current breast cancer
- Participants must not have current or anticipated use of other investigational
agents while participating in this study
- Participants must not have history of allergic reactions attributed to compounds of
similar chemical or biologic composition as study agents
- Participants must not have severe hypersensitivity (>= grade 3) to pembrolizumab or
any of its excipients
- Participants must not have received prior therapy with an anti-PD-1, anti-PD-L1, or
anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory
T-cell receptor (e.g. CTLA-4, OX-40, CD137)
- Participants must not be currently participating in or have participated in a study
of an investigational agent or used an investigational device within 28 days prior
to randomization
- Participants must be >= 18 years old
- Participants must have Zubrod performance status of 0-2
- Participants with evidence of peripheral neuropathy must have it at =< grade 1, by
Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0, within 28
days prior to randomization
- Participants must have a complete medical history and physical exam within 28 days
prior to randomization
- Hemoglobin >= 9.0 g/dL or >= 5.6 mol/L (within 28 days prior to randomization)
- (Criteria must be met without erythropoietin dependency and without packed red
blood cell transfusion within last 2 weeks)
- Leukocytes >= 3 x 10^3/uL (within 28 days prior to randomization)
- Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to randomization)
- Platelets >= 100 x 10^3/uL (within 28 days prior to randomization)
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN), OR direct
bilirubin =< IULN for participants with total bilirubin > 1.5 x IULN (unless history
of Gilbert's disease. Participants with history of Gilbert's disease must have total
bilirubin =< 5 x institutional IULN) (within 28 days prior to randomization)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x
institutional upper limit of normal (ULN) (within 28 days prior to randomization)
- Participants must have a serum creatinine =< the IULN OR calculated creatinine
clearance >= 50 mL/min/1.73m^2 using the following Cockcroft-Gault Formula. This
specimen must have been drawn and processed within 28 days prior to registration
- Participants must have adequate cardiac function. Participants must have left
ventricular ejection fraction >= 50% as assessed by either echocardiography (ECHO)
or multigated acquisition scan (MUGA) assessed within 28 days prior to registration.
Participants with known history or current symptoms of cardiac disease, or history
of treatment with cardiotoxic agents, must have a clinical risk assessment of
cardiac function using the New York Heart Association Functional Classification and
must be class 2B or better
- Participants with known human immunodeficiency virus (HIV)-infection must be on
effective anti-retroviral therapy at randomization and have undetectable viral load
test on the most recent test results obtained within 6 months prior to randomization
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load while on suppressive therapy on the most recent test
results obtained within 6 months prior to randomization, if indicated
- Note: No testing for Hepatitis B is required unless mandated by local health
authority
- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants currently being treated for HCV infection must have
undetectable HCV viral load test on the most recent test results obtained within 6
months prior to randomization, if indicated
- Note: No testing for hepatitis C is required unless mandated by local health
authority
- Participants with history of diabetes must not have uncontrolled diabetes in the
opinion of the treating investigator
- Participants must not have uncontrolled hypertension in the opinion of the treating
investigator
- Participants must not have had a major surgery within 14 days prior to
randomization. Participants must have fully recovered from the effects of prior
major surgery in the opinion of the treating investigator
- Participants must not have severe or active infections within 14 days prior to
Randomization, including but not limited to hospitalization for infection,
bacteremia, or severe pneumonia
- Participants must not have a diagnosis of immunodeficiency and be receiving chronic
systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)
or any other form of immunosuppressive therapy within 7 days prior to randomization
- Participants must not have active autoimmune disease that has required systemic
treatment in 2 years prior to randomization (i.e., with use of disease modifying
agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g.,
thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or
pituitary insufficiency) is not considered a form of systemic treatment
- Participants must not have a history of (non-infectious) pneumonitis that required
steroids, or has current (non-infectious) pneumonitis
- Participants must not have received a live vaccine within 30 days prior to
randomization. Examples of live vaccines include, but are not limited to, the
following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever,
rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza
vaccines for injection are generally killed virus vaccines and are allowed; however,
intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live
attenuated vaccines and are not allowed
- Participants must not have a prior or concurrent malignancy whose natural history or
treatment (in the opinion of the treating physician) has the potential to interfere
with the safety or efficacy assessment of the treatment regimen
- Participants must not be pregnant or nursing. Individuals who are of reproductive
potential must have agreed to use an effective contraceptive method with details
provided as a part of the consent process. A person who has had menses at any time
in the preceding 12 consecutive months or who has semen likely to contain sperm is
considered to be of "reproductive potential." In addition to routine contraceptive
methods, "effective contraception" also includes refraining from sexual activity
that might result in pregnancy and surgery intended to prevent pregnancy (or with a
side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy,
bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in
the semen
- Participants must have one (1) physical 4-5-micron single hematoxylin and eosin
(H&E) slide from the archival pretreatment diagnostic biopsy available for
submission
- Participants must be offered the opportunity to participate in specimen banking.
With participant consent, specimens must be collected and submitted via the
Southwest Oncology Group (SWOG) Specimen Tracking System
- Participants who can complete questionnaires in English, Spanish, or French must be
offered the opportunity to participate in the Patient-Reported Outcome study
- NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration
process the treating institution's identity is provided in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered in the system
- Participants must be informed of the investigational nature of this study and
must sign and give informed consent in accordance with institutional and
federal guidelines
- For participants with impaired decision-making capabilities, legally authorized
representatives may sign and give informed consent on behalf of study
participants in accordance with applicable federal, local, and Central
Institutional Review Board (CIRB) regulations
- As part of the registration process the treating institution's identity is provided
in order to ensure that the current (within 365 days) date of institutional review
board approval for this study has been entered in the system
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm I (usual chemo-immunotherapy) |
Patients receive paclitaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial. |
|
|
Experimental Arm II (shorter chemo-immunotherapy) |
Patients receive docetaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial. |
|
Recruiting Locations
Anchorage 5879400, Alaska 5879092 98508
Anchorage 5879400, Alaska 5879092 99504
Anchorage 5879400, Alaska 5879092 99508
Anchorage 5879400, Alaska 5879092 99508
Anchorage 5879400, Alaska 5879092 99508
Anchorage 5879400, Alaska 5879092 99508
Anchorage 5879400, Alaska 5879092 99508
Anchorage 5879400, Alaska 5879092 99508
Phoenix 5308655, Arizona 5551752 85004
Fort Smith 4111410, Arkansas 4099753 72903
Site Public Contact
800-378-9373
Jonesboro 4116834, Arkansas 4099753 72401
Little Rock 4119403, Arkansas 4099753 72205
Arroyo Grande 5324802, California 5332921 93420
Auburn 5325223, California 5332921 95602
Auburn 5325223, California 5332921 95603
Berkeley 5327684, California 5332921 94704
Beverly Hills 5328041, California 5332921 90211
Burbank 5331835, California 5332921 91505
Cameron Park 5333282, California 5332921 95682
Carmichael 5334336, California 5332921 95608
Carmichael 5334336, California 5332921 95608
Castro Valley 5334928, California 5332921 94546
Davis 5341704, California 5332921 95616
Elk Grove 5346111, California 5332921 95758
Fremont 5350734, California 5332921 94538
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Modesto 5373900, California 5332921 95355
Mountain View 5375480, California 5332921 94040
Mountain View 5375480, California 5332921 94040
Napa 5376095, California 5332921 94558
Site Public Contact
707-521-3830
Novato 5378044, California 5332921 94945
Palm Springs 5380668, California 5332921 92262
Site Public Contact
760-416-4730
Palo Alto 5380748, California 5332921 94301
Rocklin 5388319, California 5332921 95765
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95816
San Francisco 5391959, California 5332921 94115
San Luis Obispo 5392323, California 5332921 93401
San Mateo 5392423, California 5332921 94401
Santa Cruz 5393052, California 5332921 95065
Santa Maria 5393180, California 5332921 93444
Santa Rosa 5393287, California 5332921 95403
Site Public Contact
707-521-3830
Santa Rosa 5393287, California 5332921 95403
Santa Rosa 5393287, California 5332921 95405
Site Public Contact
707-521-3830
Sunnyvale 5400075, California 5332921 94086
Tarzana 5401143, California 5332921 91356
Site Public Contact
818-981-3818
Torrance 5403022, California 5332921 90505
Vallejo 5405380, California 5332921 94589
Woodland 5410430, California 5332921 95695
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80923
Denver 5419384, Colorado 5417618 80206
Denver 5419384, Colorado 5417618 80210
Denver 5419384, Colorado 5417618 80218
Durango 5420241, Colorado 5417618 81301
Durango 5420241, Colorado 5417618 81301
Golden 5423294, Colorado 5417618 80401
Golden 5423294, Colorado 5417618 80401
Lakewood 5427946, Colorado 5417618 80228
Littleton 5429032, Colorado 5417618 80122
Longmont 5579276, Colorado 5417618 80501
Parker 5434006, Colorado 5417618 80138
Pueblo 5435464, Colorado 5417618 81004
Thornton 5441492, Colorado 5417618 80260
Wheat Ridge 5443948, Colorado 5417618 80033
Frankford 4142601, Delaware 4142224 19945
Lewes 4143354, Delaware 4142224 19958
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19718
Rehoboth Beach 4144284, Delaware 4142224 19971
Wilmington 4145381, Delaware 4142224 19801
Lakeland 4161438, Florida 4155751 33805
Site Public Contact
863-680-7780
Thomasville 4226348, Georgia 4197000 31792
Boise 5586437, Idaho 5596512 83706
Boise 5586437, Idaho 5596512 83712
Caldwell 5587698, Idaho 5596512 83605
Coeur d'Alene 5589173, Idaho 5596512 83814
Emmett 5592562, Idaho 5596512 83617
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83686
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Twin Falls 5610810, Idaho 5596512 83301
Alton 4232679, Illinois 4896861 62002
Site Public Contact
618-463-5623
Aurora 4883817, Illinois 4896861 60504
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carbondale 4235193, Illinois 4896861 62902
Carterville 4235311, Illinois 4896861 62918
Carthage 4886716, Illinois 4896861 62321
Centralia 4235587, Illinois 4896861 62801
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60611
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Galesburg 4893392, Illinois 4896861 61401
Site Public Contact
309-344-2831
Geneva 4893591, Illinois 4896861 60134
Kewanee 4898433, Illinois 4896861 61443
Lake Forest 4899012, Illinois 4896861 60045
Macomb 4900817, Illinois 4896861 61455
Mattoon 4244099, Illinois 4896861 61938
Mount Vernon 4245152, Illinois 4896861 62864
Site Public Contact
618-242-4600
O'Fallon 4245926, Illinois 4896861 62269
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61636
Peru 4905770, Illinois 4896861 61354
Peru 4905770, Illinois 4896861 61354
Site Public Contact
815-664-4141
Princeton 4906818, Illinois 4896861 61356
Rockford 4907959, Illinois 4896861 61114
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Warrenville 4915525, Illinois 4896861 60555
Washington 4915545, Illinois 4896861 61571
Yorkville 4917298, Illinois 4896861 60560
Richmond 4263681, Indiana 4921868 47374
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-363-2690
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Clive 4852065, Iowa 4862182 50325
Council Bluffs 4852832, Iowa 4862182 51503
Creston 4853078, Iowa 4862182 50801
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
West Des Moines 4881346, Iowa 4862182 50266
Chanute 4269392, Kansas 4273857 66720
Dodge City 5445298, Kansas 4273857 67801
El Dorado 4270863, Kansas 4273857 67042
Garden City 5445439, Kansas 4273857 67846
Great Bend 4272340, Kansas 4273857 67530
Hays 4272782, Kansas 4273857 67601
Site Public Contact
785-623-5774
Independence 4273359, Kansas 4273857 67301
Kingman 4273978, Kansas 4273857 67068
Lawrence 4274277, Kansas 4273857 66044
Liberal 5445820, Kansas 4273857 67905
Manhattan 4274994, Kansas 4273857 66502
McPherson 4275261, Kansas 4273857 67460
Newton 4276248, Kansas 4273857 67114
Olathe 4276614, Kansas 4273857 66061
Parsons 4277011, Kansas 4273857 67357
Pratt 4277752, Kansas 4273857 67124
Salina 4278890, Kansas 4273857 67401
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Wellington 4281386, Kansas 4273857 67152
Wichita 4281730, Kansas 4273857 67208
Wichita 4281730, Kansas 4273857 67214
Wichita 4281730, Kansas 4273857 67214
Winfield 4281897, Kansas 4273857 67156
Bardstown 4283133, Kentucky 6254925 40004
Corbin 4288656, Kentucky 6254925 40701
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40509
London 4298960, Kentucky 6254925 40741
Mount Sterling 4301683, Kentucky 6254925 40353
New Orleans 4335045, Louisiana 4331987 70112
New Orleans 4335045, Louisiana 4331987 70112
Elkton 4354234, Maryland 4361885 21921
Beverly 4930505, Massachusetts 6254926 01915
Site Public Contact
978-922-3000
Burlington 4931737, Massachusetts 6254926 01805
Gloucester 4937829, Massachusetts 6254926 01930
Site Public Contact
978-283-4000
Peabody 4946863, Massachusetts 6254926 01960
Winchester 4955884, Massachusetts 6254926 01890
Adrian 4983811, Michigan 5001836 49221
Site Public Contact
517-265-0116
Ann Arbor 4984247, Michigan 5001836 48106
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Caro 4988059, Michigan 5001836 48723
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Clarkston 4988997, Michigan 5001836 48346
Clarkston 4988997, Michigan 5001836 48346
Dearborn 4990510, Michigan 5001836 48124
Site Public Contact
248-551-7695
Detroit 4990729, Michigan 5001836 48236
East China Township, Michigan 5001836 48054
Farmington Hills 4992523, Michigan 5001836 48336
Site Public Contact
248-551-7695
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Grosse Pointe Woods 4994871, Michigan 5001836 48236
Grosse Pointe Woods 4994871, Michigan 5001836 48236
Lansing 4998830, Michigan 5001836 48912
Site Public Contact
517-364-9400
Livonia 4999837, Michigan 5001836 48154
Macomb 5000473, Michigan 5001836 48044
Marlette 5000938, Michigan 5001836 48453
Monroe 5002344, Michigan 5001836 48162
Site Public Contact
800-444-3561
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Royal Oak 5007804, Michigan 5001836 48067
Site Public Contact
248-551-7695
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Saginaw 5007989, Michigan 5001836 48601
Saginaw 5007989, Michigan 5001836 48604
Sterling Heights 5011148, Michigan 5001836 48312
Sterling Heights 5011148, Michigan 5001836 48312
Site Public Contact
248-551-7695
Tawas City 5011900, Michigan 5001836 48764
Troy 5012639, Michigan 5001836 48084
Site Public Contact
248-551-7695
Troy 5012639, Michigan 5001836 48085
Site Public Contact
248-551-7695
Troy 5012639, Michigan 5001836 48098
Site Public Contact
248-551-7695
Warren 5014051, Michigan 5001836 48088
Warren 5014051, Michigan 5001836 48093
Warren 5014051, Michigan 5001836 48093
Warren 5014051, Michigan 5001836 48093
Warren 5014051, Michigan 5001836 48093
West Branch 5014413, Michigan 5001836 48661
Ypsilanti 5015688, Michigan 5001836 48106
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Burnsville 5019767, Minnesota 5037779 55337
Cambridge 5020068, Minnesota 5037779 55008
Coon Rapids 5022025, Minnesota 5037779 55433
Edina 5025264, Minnesota 5037779 55435
Maple Grove 5036493, Minnesota 5037779 55369
Maplewood 5036588, Minnesota 5037779 55109
Maplewood 5036588, Minnesota 5037779 55109
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Minneapolis 5037649, Minnesota 5037779 55454
Monticello 5038045, Minnesota 5037779 55362
New Ulm 5039173, Minnesota 5037779 56073
Princeton 5042360, Minnesota 5037779 55371
Robbinsdale 5043439, Minnesota 5037779 55422
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Shakopee 5046997, Minnesota 5037779 55379
Stillwater 5048814, Minnesota 5037779 55082
Thief River Falls 5049970, Minnesota 5037779 56701
Site Public Contact
605-312-3320
Waconia 5051640, Minnesota 5037779 55387
Willmar 5052916, Minnesota 5037779 56201
Woodbury 5053358, Minnesota 5037779 55125
Worthington 5053460, Minnesota 5037779 56187
Site Public Contact
605-312-3320
Wyoming 5053526, Minnesota 5037779 55092
Columbus 4422442, Mississippi 4436296 39705
Grenada 4428539, Mississippi 4436296 38901
Jackson 4431410, Mississippi 4436296 39216
Site Public Contact
601-815-6700
New Albany 4438121, Mississippi 4436296 38652
Oxford 4440076, Mississippi 4436296 38655
Southhaven 4446702, Mississippi 4436296 38671
Ballwin 4375663, Missouri 4398678 63011
Site Public Contact
314-251-7058
Bolivar 4377835, Missouri 4398678 65613
Branson 4378219, Missouri 4398678 65616
Site Public Contact
417-269-4520
Cape Girardeau 4379966, Missouri 4398678 63703
Cape Girardeau 4379966, Missouri 4398678 63703
Site Public Contact
573-651-5550
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Jefferson City 4392388, Missouri 4398678 65109
Joplin 4392768, Missouri 4398678 64804
Joplin 4392768, Missouri 4398678 64804
Kansas City 4393217, Missouri 4398678 64108
Site Public Contact
816-404-4375
Osage Beach 4402040, Missouri 4398678 65065
Rolla 4406282, Missouri 4398678 65401
Rolla 4406282, Missouri 4398678 65401
Site Public Contact
573-458-6379
Saint Joseph 4407010, Missouri 4398678 64506
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
Springfield 4409896, Missouri 4398678 65807
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63109
Site Public Contact
314-353-1870
St Louis 4407066, Missouri 4398678 63128
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Washington 4413621, Missouri 4398678 63090
Site Public Contact
636-390-1600
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Great Falls 5655240, Montana 5667009 59405
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Missoula 5666639, Montana 5667009 59802
Missoula 5666639, Montana 5667009 59804
Kearney 5071348, Nebraska 5073708 68847
Lincoln 5072006, Nebraska 5073708 68510
Omaha 5074472, Nebraska 5073708 68122
Omaha 5074472, Nebraska 5073708 68124
Omaha 5074472, Nebraska 5073708 68130
Omaha 5074472, Nebraska 5073708 68131
Papillion 5074792, Nebraska 5073708 68046
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Valley Stream 5142109, New York 5128638 11580
Asheville 4453066, North Carolina 4482348 28803
Clyde 4461150, North Carolina 4482348 28721
Hendersonville 4470592, North Carolina 4482348 28791
Hendersonville 4470592, North Carolina 4482348 28792
Pinehurst 4485272, North Carolina 4482348 28374
Weaverville 4497912, North Carolina 4482348 28787
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58103
Site Public Contact
701-234-6161
Fargo 5059163, North Dakota 5690763 58103
Site Public Contact
605-312-3320
Fargo 5059163, North Dakota 5690763 58104
Site Public Contact
800-437-4010
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Beavercreek 4506008, Ohio 5165418 45431
Boardman 5147784, Ohio 5165418 44512
Centerville 4508204, Ohio 5165418 45459
Centerville 4508204, Ohio 5165418 45459
Cincinnati 4508722, Ohio 5165418 45220
Cincinnati 4508722, Ohio 5165418 45236
Cincinnati 4508722, Ohio 5165418 45242
Cincinnati 4508722, Ohio 5165418 45247
Cincinnati 4508722, Ohio 5165418 45255
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45415
Dayton 4509884, Ohio 5165418 45415
Findlay 5153924, Ohio 5165418 45840
Findlay 5153924, Ohio 5165418 45840
Findlay 5153924, Ohio 5165418 45840
Franklin 4512203, Ohio 5165418 45005-1066
Franklin 4512203, Ohio 5165418 45005
Greenville 5156493, Ohio 5165418 45331
Greenville 5156493, Ohio 5165418 45331
Kettering 4515843, Ohio 5165418 45409
Kettering 4515843, Ohio 5165418 45429
Maumee 5162137, Ohio 5165418 43537
Toledo 5174035, Ohio 5165418 43623
Site Public Contact
800-444-3561
Troy 5174358, Ohio 5165418 45373
Troy 5174358, Ohio 5165418 45373
Warren 5175865, Ohio 5165418 44484
Youngstown 5177568, Ohio 5165418 44501
Oklahoma City 4544349, Oklahoma 4544379 73104
Oklahoma City 4544349, Oklahoma 4544379 73120
Site Public Contact
405-752-3402
Baker City 5712169, Oregon 5744337 97814
Bend 5713587, Oregon 5744337 97701
Clackamas 5719308, Oregon 5744337 97015
Clackamas 5719308, Oregon 5744337 97015
Coos Bay 5720495, Oregon 5744337 97420
Gresham 5729485, Oregon 5744337 97030
Site Public Contact
503-413-2150
Newberg 5742726, Oregon 5744337 97132
Ontario 5744166, Oregon 5744337 97914
Oregon City 5744253, Oregon 5744337 97045
Portland 5746545, Oregon 5744337 97210
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Redmond 5747882, Oregon 5744337 97756
Site Public Contact
541-706-2909
Tualatin 5757506, Oregon 5744337 97062
Site Public Contact
503-413-1742
Allentown 5178127, Pennsylvania 6254927 18103
Bethlehem 5180225, Pennsylvania 6254927 18017
Bryn Mawr 5182063, Pennsylvania 6254927 19010
Chadds Ford 4557084, Pennsylvania 6254927 19317
Collegeville 5184966, Pennsylvania 6254927 19426
East Stroudsburg 5188075, Pennsylvania 6254927 18301
Exton 5189022, Pennsylvania 6254927 19341
Hazleton 5193011, Pennsylvania 6254927 18201
Media 4559575, Pennsylvania 6254927 19063
Newtown Square 4560006, Pennsylvania 6254927 19073
Paoli 5205037, Pennsylvania 6254927 19301
Wynnewood 5220230, Pennsylvania 6254927 19096
Providence 5224151, Rhode Island 5224323 02905
Site Public Contact
401-274-1122
Boiling Springs 4571805, South Carolina 4597040 29316
Site Public Contact
864-241-6251
Easley 4577263, South Carolina 4597040 29640
Greenville 4580543, South Carolina 4597040 29605
Site Public Contact
864-241-6251
Greenville 4580543, South Carolina 4597040 29605
Site Public Contact
864-241-6251
Greenville 4580543, South Carolina 4597040 29615
Site Public Contact
864-241-6251
Greer 4580599, South Carolina 4597040 29650
Site Public Contact
864-241-6251
Seneca 4595346, South Carolina 4597040 29672
Site Public Contact
864-241-6251
West Columbia 4600541, South Carolina 4597040 29169
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Collierville 4614748, Tennessee 4662168 38017
Memphis 4641239, Tennessee 4662168 38120
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23113
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23223
Richmond 4781708, Virginia 6254928 23226
Richmond 4781708, Virginia 6254928 23230
Aberdeen 5785243, Washington 5815135 98520
Bellingham 5786899, Washington 5815135 98225
Site Public Contact
360-788-8223
Bremerton 5788054, Washington 5815135 98310
Centralia 5789683, Washington 5815135 98531
Edmonds 5793427, Washington 5815135 98026
Everett 5793933, Washington 5815135 98201
Issaquah 5798487, Washington 5815135 98029
Kennewick 5799610, Washington 5815135 99336
Lacey 5800112, Washington 5815135 98503
Longview 5801617, Washington 5815135 98632
Seattle 5809844, Washington 5815135 98107
Seattle 5809844, Washington 5815135 98122-5711
Seattle 5809844, Washington 5815135 98122
Sedro-Woolley 5809902, Washington 5815135 98284
Shelton 5810176, Washington 5815135 98584
Vancouver 5814616, Washington 5815135 98664
Vancouver 5814616, Washington 5815135 98684
Vancouver 5814616, Washington 5815135 98686
Site Public Contact
503-413-2150
Walla Walla 5814916, Washington 5815135 99362
Yelm 5816656, Washington 5815135 98597
Eau Claire 5251436, Wisconsin 5279468 54701
Marshfield 5261969, Wisconsin 5279468 54449
Minocqua 5263156, Wisconsin 5279468 54548
New Richmond 5264475, Wisconsin 5279468 54017
Rice Lake 5268798, Wisconsin 5279468 54868
Stevens Point 5274644, Wisconsin 5279468 54482
Weston 5278693, Wisconsin 5279468 54476
Cody 5821593, Wyoming 5843591 82414
Sheridan 5838198, Wyoming 5843591 82801
Bayamón 4562831, Puerto Rico 00959-5060
Site Public Contact
787-395-7085
Manatí 4566137, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan 4568127, Puerto Rico 00917
Site Public Contact
787-274-3387
San Juan 4568127, Puerto Rico 00927
San Juan 4568127, Puerto Rico 00927
San Juan 4568127, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT05929768
- Status
- Recruiting
- Sponsor
- SWOG Cancer Research Network
Detailed Description
PRIMARY OBJECTIVE: I. To assess whether participants with early stage triple negative breast cancer (TNBC) randomized to receive anthracycline-free, taxane-platinum neoadjuvant chemotherapy with pembrolizumab have non-inferior breast cancer event-free survival (BC-EFS) compared to participants randomized to taxane-platinum-anthracycline neoadjuvant chemotherapy with pembrolizumab. SECONDARY OBJECTIVES: I. To compare pathological complete response (pCR) and residual cancer burden (RCB) rates by randomized arm. II. To compare pCR and RCB rates between randomized arms by tumor infiltrating lymphocytes (TIL) status. III. To compare BC-EFS between randomized arms in the TIL-enriched and non-TIL enriched subgroups. IV. To compare distant relapse-free survival and overall survival by randomized arm. V. To compare invasive breast cancer-free survival after surgery between randomized arms in pCR and residual disease groups. VI. To compare the safety and tolerability by randomized arm among those that initiate therapy. TRANSLATIONAL MEDICINE OBJECTIVE: I. To evaluate concordance and accuracy of an automated stromal TIL (sTIL) algorithm versus (vs.) central pathologist assessed sTILs quantification. PATIENT REPORTED OUTCOME (PRO) OBJECTIVES: I. To compare patient-reported fatigue at 3 weeks after the last neoadjuvant systemic therapy (NAST) dose and, separately, at 18 months after randomization, using the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue-7a in participants undergoing NAST with taxane-platinum-anthracycline chemo-immunotherapy vs taxane-platinum chemo-immunotherapy. (Quality of Life, Primary) II. To compare physical function experienced by participants undergoing neoadjuvant systemic chemotherapy (NAST) with taxane-platinum-anthracycline chemo-immunotherapy vs taxane-platinum chemo-immunotherapy, within 3-5 weeks post last neoadjuvant systemic therapy dose using the PROMIS-29 Profile physical function subscale score. (Quality of Life, Secondary) III. To compare physical function experienced by participants undergoing NAST taxane-platinum-anthracycline chemo-immunotherapy vs taxane-platinum chemo-immunotherapy at 18 months post registration using the PROMIS-29 Profile physical function subscale score. (Quality of Life, Secondary) IV. To compare other PROMIS-29 Profile subscale scores (sleep disturbance, depression, anxiety, social, pain interference, and pain sensitivity) and GP5 question response by arm within 3-5 weeks post last neoadjuvant systemic therapy dose and at 18 months post registration. (Quality of Life, Exploratory) V. To compare the GP-5 item scores by arm within 3-5 weeks post last neoadjuvant systemic therapy dose and at 18 months post registration. (Quality of Life, Exploratory) VI. To compare select patient-reported outcomes using the Common Terminology Criteria for Adverse Events (PRO-CTCAE) by arm. (Patient-Reported Symptoms of Treatment) BANKING OBJECTIVE: I. To bank physical specimens and digital slides for future correlative studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive paclitaxel intravenously (IV), carboplatin IV, and pembrolizumab IV on study. Patients then receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial. ARM II: Patients receive docetaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial. Patients are followed up every 6 months for the first 2 years and then annually until 5 years from registration.